articleTop 1% cited

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology · 2019 · Vol. 20(2) · pp. 282–296

Andrew X. Zhu✉(Massachusetts General Hospital)Yoon‐Koo Kang(Asan Medical Center)Chia‐Jui Yen(National Cheng Kung University Hospital)Richard S. Finn(University of California, Los Angeles)Peter R. Galle(Johannes Gutenberg University Mainz)Josep M. Llovet(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer)Eric Assénat(Centre Hospitalier Universitaire de Montpellier)Giovanni Brandi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola)Marc Pracht(Centre Eugène Marquis)Ho Yeong Lim(Samsung Medical Center)Kun‐Ming Rau(E-Da Hospital)Kenta Motomura(Aso Iizuka Hospital)Izumi Ohno(National Cancer Center Hospital East)Philippe Merle(Hôpital de la Croix-Rousse)Bruno Daniele(Azienda Ospedaliera G.Rummo)Dong Bok Shin(Gachon University Gil Medical Center)Guido Gerken(Essen University Hospital)Christophe Borg(Centre Hospitalier Universitaire de Besançon)Jean‐Baptiste Hiriart(Centre Hospitalier Universitaire de Bordeaux)Takuji Okusaka(Tokyo National Hospital)Manabu Morimoto(Kanagawa Prefectural Hospital Organization)Yanzhi Hsu(Eli Lilly (United States))Paolo Abada(Eli Lilly (United States))Masatoshi Kudo(Kindai University)

View via DOI Publisher page

Hepatocellular Carcinoma Treatment and Prognosis Cholangiocarcinoma and Gallbladder Cancer Studies Pancreatic and Hepatic Oncology ResearchRamucirumabMedicineSorafenibHepatocellular carcinomaInternal medicinePlaceboClinical endpointCirrhosisGastroenterologyLiver cancer

MeSH terms

SorafenibRamucirumabAgedalpha-FetoproteinsAntineoplastic AgentsDouble-Blind MethodDrug Therapy, CombinationFemaleCarcinoma, HepatocellularHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingTreatment Outcome